Barnes A, Ooi S, Lynch K, Parthasarathy N, Bishara M, Gounder M
Dig Dis Sci. 2022; 68(3):889-896.
PMID: 35687221
PMC: 10011286.
DOI: 10.1007/s10620-022-07556-y.
Gordon M, Grafton-Clarke C, Akobeng A, Macdonald J, Chande N, Hanauer S
Frontline Gastroenterol. 2022; 12(5):423-436.
PMID: 35401955
PMC: 8989005.
DOI: 10.1136/flgastro-2020-101405.
Lodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M
Prz Gastroenterol. 2022; 16(4):257-296.
PMID: 34976235
PMC: 8690943.
DOI: 10.5114/pg.2021.110914.
Rui M, Fei Z, Wang Y, Shi F, Meng R, Shang Y
Front Med (Lausanne). 2021; 8:679258.
PMID: 34540859
PMC: 8440847.
DOI: 10.3389/fmed.2021.679258.
Gargallo-Puyuelo C, Laredo V, Gomollon F
Front Med (Lausanne). 2021; 8:681907.
PMID: 34336887
PMC: 8322650.
DOI: 10.3389/fmed.2021.681907.
Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?.
Luber R, Honap S, Cunningham G, Irving P
Front Med (Lausanne). 2019; 6:279.
PMID: 31850357
PMC: 6892750.
DOI: 10.3389/fmed.2019.00279.
Immunosuppressive therapies adversely affect blood biochemical parameters in patients with inflammatory bowel disease: a meta-analysis.
Wang X, Wang G, Shang J, Pan H, Zhang X, Zhou F
J Int Med Res. 2019; 47(8):3534-3549.
PMID: 31364448
PMC: 6726787.
DOI: 10.1177/0300060519864800.
Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.
Vasudevan A, Raghunath A, Anthony S, Scanlon C, Sparrow M, Gibson P
Dig Dis Sci. 2018; 64(6):1622-1631.
PMID: 30560332
DOI: 10.1007/s10620-018-5422-8.
Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
Johnson C, Dassopoulos T
Curr Gastroenterol Rep. 2018; 20(11):53.
PMID: 30267281
DOI: 10.1007/s11894-018-0658-1.
ACG Clinical Guideline: Management of Crohn's Disease in Adults.
Lichtenstein G, Loftus E, Isaacs K, Regueiro M, Gerson L, Sands B
Am J Gastroenterol. 2018; 113(4):481-517.
PMID: 29610508
DOI: 10.1038/ajg.2018.27.
Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.
Jeuring S, Biemans V, van den Heuvel T, Zeegers M, Hameeteman W, Romberg-Camps M
Am J Gastroenterol. 2018; 113(3):384-395.
PMID: 29317770
DOI: 10.1038/ajg.2017.482.
Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?.
Vasudevan A, Gibson P, van Langenberg D
World J Gastroenterol. 2017; 23(35):6385-6402.
PMID: 29085188
PMC: 5643264.
DOI: 10.3748/wjg.v23.i35.6385.
Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective.
Axelrad J, Roy A, Lawlor G, Korelitz B, Lichtiger S
World J Gastroenterol. 2016; 22(46):10103-10117.
PMID: 28028358
PMC: 5155169.
DOI: 10.3748/wjg.v22.i46.10103.
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N, Townsend C, Parker C, MacDonald J
Cochrane Database Syst Rev. 2016; 10:CD000545.
PMID: 27783843
PMC: 6464152.
DOI: 10.1002/14651858.CD000545.pub5.
Approach to the Patient with Mild Crohn's Disease: a 2016 Update.
Scott F, Lichtenstein G
Curr Gastroenterol Rep. 2016; 18(9):50.
PMID: 27448619
DOI: 10.1007/s11894-016-0523-z.
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
Chande N, Patton P, Tsoulis D, Thomas B, MacDonald J
Cochrane Database Syst Rev. 2015; (10):CD000067.
PMID: 26517527
PMC: 9578512.
DOI: 10.1002/14651858.CD000067.pub3.
NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.
Kakuta Y, Naito T, Onodera M, Kuroha M, Kimura T, Shiga H
Pharmacogenomics J. 2015; 16(3):280-5.
PMID: 26076924
DOI: 10.1038/tpj.2015.43.
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.
Quetglas E, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M
Eur J Clin Pharmacol. 2015; 71(7):773-99.
PMID: 26008212
DOI: 10.1007/s00228-015-1862-7.
Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability.
Shah E, Siegel C, Chong K, Melmed G
Dig Dis Sci. 2015; 60(8):2408-18.
PMID: 25772778
DOI: 10.1007/s10620-015-3618-8.
Steroid use in Crohn's disease.
Vavricka S, Schoepfer A, Scharl M, Rogler G
Drugs. 2014; 74(3):313-24.
PMID: 24532122
DOI: 10.1007/s40265-014-0183-y.
